Corrective Phases R...
Health Care: Drugs
Agenus Inc. (AGEN: NASDAQ)
$2.48 0.06 | 2.48%
12/01/11 - 04:00 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 2.76M | 3.36M | 3.33M | 2.65M |
| Cost of Sales | -2.25M | -3.31M | -4.11M | -4.67M |
| Gross Operating Profit | 5.01M | 6.67M | 7.44M | 7.33M |
| Selling, General, and Administrative Expenses | 10.82M | 12.11M | 14.11M | 19.83M |
| Research & Development | 11.02M | 12.88M | 16.90M | 20.66M |
| Operating Income before D & A (EBITDA) | -16.83M | -18.31M | -23.57M | -33.17M |
| Depreciation & Amortization | 2.25M | 3.44M | 4.11M | 4.67M |
| Interest Income | 18.79K | 37.56K | 137.48K | 0.00 |
| Other Income - Net | 1.94K | 4.68M | 2.57M | 14.23M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -19.07M | -17.03M | -24.97M | -23.62M |
| Interest Expense | 4.21M | 4.87M | 5.34M | 5.08M |
| Pre-Tax Income | -23.28M | -21.91M | -30.32M | -28.70M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -23.28M | -21.91M | -30.32M | -28.70M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -23.28M | -21.91M | -30.32M | -28.70M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -23.28M | -21.91M | -30.32M | -28.70M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-23.28M | -21.91M | -30.32M | -28.70M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -24.07M | -22.70M | -31.11M | -29.49M |
| Basic EPS from Continuing Ops. | -1.21 | -1.38 | -2.34 | -2.82 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.21 | -1.38 | -2.34 | -2.82 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.21 | -1.38 | -2.34 | -2.82 |
| Basic Normalized Net Income/Share | -1.21 | -1.38 | -2.34 | -2.82 |
| EPS fr Continuing Ops. | -1.21 | -1.38 | -2.34 | -2.82 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.21 | -1.38 | -2.34 | -2.82 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.21 | -1.38 | -2.34 | -2.82 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.21 | -1.38 | -2.34 | -2.82 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with AGEN
- Portfolio NameUser Type
- UserKJP Save Stockpickr Fund
- ContributorStocks Under-$10 Moving Hig...
- ProRobert Bruce
- Contributor16 Small-Cap Stocks in Dang...
- UserASCO 2010
- Userhp22puch Portfolio 1
- Usernvoelz Portfolio 1
- UserPix's Stocks
- UserArsenD Portfolio 1
- UserMikejo10 Portfolio 1
Latest AGEN Headlines from TheStreet
- Biotech Stock Mailbag: All You Need to Know About Hep C Drugs 04.13.12 | 05:04 am
- 3 Stocks Under $10 Moving Higher 03.29.12 | 12:03 pm
- Agenus' CEO Discusses Q4 2011 Results - Earnings Call Transcript 03.05.12 | 03:03 pm
- Agenus Only Gets A Mosquito-Sized Bite of the New And Heralded Malaria Vaccine 10.18.11 | 03:10 pm
- Agenus Stock Gaps Down On Today's Open (AGEN) 10.07.11 | 09:10 am
- Agenus' CEO Discusses Q2 2011 Results - Earnings Call Transcript 07.29.11 | 10:07 pm
- Oncothyreon: Deep Dive Into Stimuvax 07.11.11 | 07:07 am
- Biotech Data Mining Comes Up Empty 06.29.11 | 07:06 am
- ASCO: Cancer Stock Winners, Losers 05.19.11 | 10:05 am
- Agenus Receives NASDAQ Delisting Notification 03.04.11 | 09:03 am
Press Releases for AGEN
- The Fourth Product Candidate Containing Antigenics' QS-21 In Phase 3 Clinical Development - Business Wire 08.25.10 | 02:08 pm
- Antigenics Reports Second Quarter 2010 Financial Results - Business Wire 07.29.10 | 07:07 am
- Antigenics Presents Positive, Top Line Data From Phase I Herpes Clinical Trial - Business Wire 07.27.10 | 07:07 am
- Antigenics To Report Second Quarter Financial Results On July 29, 2010; Conference Call To Follow - Business Wire 07.22.10 | 07:07 am
- Antigenics Receives NASDAQ Delisting Notification - Business Wire 07.21.10 | 04:07 pm
- Encouraging Data Presented On Oncophage® Vaccine At International Conference On Brain Tumor Research And Therapy - Business Wire 05.20.10 | 07:05 am
- Antigenics To Webcast 2010 Annual Shareholders Meeting - Business Wire 04.29.10 | 07:04 am
- Antigenics Reports First Quarter 2010 Financial Results - Business Wire 04.29.10 | 07:04 am
- Antigenics To Report First Quarter Financial Results On April 29, 2010; Conference Call To Follow - Business Wire 04.22.10 | 07:04 am
- Antigenics To Report Fourth Quarter And Year-End 2009 Financial Results On February 18, 2010; Conference Call To Follow - Business Wire 02.11.10 | 07:02 am
Partner Headlines for AGEN
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 05.17.12 | 09:05 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 05.14.12 | 09:05 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- Market Update - Benzinga 03.20.12 | 09:03 am
- Agenus Continues to Outperform - Seeking Alpha 03.16.12 | 06:03 pm
- 7 Biotech Stocks Being Snapped Up By Insiders - Seeking Alpha 03.16.12 | 05:03 pm
- Agenus Still Gaining On GSK Agreement Expansion - Seeking Alpha 03.15.12 | 08:03 am
- Insider Buys May Send The Wrong Signals - Seeking Alpha 08.22.11 | 09:08 am
- ASCO 2011: Opportunities for Biotech Investor Success and Failure - Seeking Alpha 05.02.11 | 09:05 am
- Antigenics changes name to Agenus - Reuters 01.06.11 | 01:01 pm
